<DOC>
	<DOCNO>NCT01859364</DOCNO>
	<brief_summary>Background : - The success rate attempt quit use tobacco product 5 percent . Many people try quit without seek professional help . Several kind nicotine replacement therapy ( NRT ) available without prescription . However , prescription drug mental health counseling also help people stop use tobacco . Combining NRT and/or medication counsel increase success rate . Researchers want study kind tobacco cessation treatment successful . This may help develop good treatment determine respond best . Objectives : - To provide treatment tobacco use . - To identify factor affect well people respond treatment . Eligibility : - Individuals least 18 year age try stop use tobacco product . Design : - This study last 1 year . Treatment may last 36 week . Treatment may include counseling , NRT ( patch and/or nicotine lozenge ) , prescription medication ( varenicline bupropion ) . Treatment determine study doctor . - Participants also three study visit 4 , 6 , 12 month start treatment . Each visit may take 2 hour . At study visit , participant different kind test . They provide blood urine sample , carbon monoxide breath test . They also fill form mood tobacco craving . - During treatment , participant clinic visit twice week counsel monitor tobacco use withdrawal symptom . Counseling session work deal tobacco craving . Each visit may take 90 minute .</brief_summary>
	<brief_title>Tobacco Cessation : Treatment Delivery Predictors Outcome</brief_title>
	<detailed_description>Objective The purpose protocol create mechanism whereby intramural program NIDA Baltimore , MD evaluate treat broad range people use tobacco product . Through protocol , participant receive state-of-the-art treatment tobacco use . The secondary objective investigate predictor success tobacco-use-cessation treatment . Study population Participants individual present NIDA IRP seek quit tobacco use ( smoked smokeless ) . Enrollment may occur part participation another NIDA IRP study . We enroll 1000 participant . All individual give sign informed consent attend least one study visit consider evaluable . We replace study dropout . Design After undergo initial screen sign IRB-approved consent form , participant enrol outpatient smoke treatment-research clinic NIDA IRP . The study last one year , active treatment last 36 week follow-up visit 4 , 6 , 12 month first treatment visit . Treatment include counsel pharmacotherapy ( nicotine replacement , bupropion , varenicline , warrant medically appropriate ) . During active treatment , participant visit clinic twice week counseling , dispense medication , monitor tobacco use , withdrawal symptom , report adverse event . Visits may take 90 minute . Outcome measure There outcome measure primary objective . For secondary objective , outcome measure ( 1 ) tobacco abstinence , determine self-reported tobacco use , urinary cotinine , ( tobacco smoker ) breath CO , ( 2 ) reduction tobacco use least 50 % ( e.g. , 10 cigarette per day 5 cigarette per day ) . Other outcome measure secondary objective include duration abstinence , nicotine withdrawal sign symptom , tobacco craving . Behavioral , psychological , medical , genetic characteristic tobacco-use history assess begin study predictor treatment outcome follow-up .</detailed_description>
	<mesh_term>Tobacco Use Disorder</mesh_term>
	<criteria>Participants individual present NIDA IRP seek help quit tobacco use ( smoked smokeless ) . We enroll 1000 participant . All individual give sign consent attend least one study visit consider evaluable . We replace study dropout . INCLUSION CRITERIA : 1 . 18 year age old 2 . Seeking help cessation tobacco use EXCLUSION CRITERIA : 1 . Inability give inform consent . 2 . Current use ( within past 30 day ) 7 FDAapproved firstline smokingcessation treatment ( varenicline , bupropion , NRTs nicotine inhaler , lozenge , patch , gum , nasal spray ) , unless administer part another NIDA IRP protocol . 3 . Any newly diagnose untreated acute medical illness require immediate medical attention . This include new medical diagnosis ( example , diabetes hypertension ) someone care physician and/or well control . An untreated acute medical illness would include acute hepatitis , acute pancreatitis , acute respiratory distress syndrome , etc . Individuals may consider participation newly diagnose condition well control acute condition resolve . ADDITIONAL EXCLUSION FOR NRT : 1 . Current major medical condition view investigator would compromise integrity data safety participant , include moderate severe cardiovascular disease ( 30 day postMI , severe worsen angina pectoris ) , lifethreatening arrhythmia , acute phase cerebrovascular accident , COPD ( emphysema chronic bronchitis ) . 2 . Current uncontrolled psychiatric condition view investigator would compromise integrity data safety participant , include bipolar disorder psychotic disorder . Uncontrolled psychiatric condition include limited : psychiatric medication change last 3 month ; psychiatric exacerbation relate hospitalization last 3 month . Individuals control Major Depressive Disorder care psychiatrist internist may consider inclusion . 3 . Pregnancy 4 . Lab value outside value list Table 1 . 5 . Nicotine patch : allergy adhesive tape , generalize chronic dermatological disorder , weight &lt; 45kg , and/or lactation ADDITIONAL EXCLUSION CRITERIA FOR VARENICLINE OR BUPROPION : 1 . Pregnancy nurse 2 . Current diagnosis schizophrenia DSMIV psychotic disorder , bipolar disorder , panic disorder , eat disorder ( current prior diagnosis ) , Major Depressive Disorder within past year require treatment , history suicide attempt 3 . History seizure , except febrile seizure childhood 4 . Current physical dependence alcohol sedativehypnotics , e.g . benzodiazepine 5 . Lab value outside value list Table 1 6 . Unstable cardiovascular disease cardiovascular event occur within two month screen 7 . For bupropion : current administration monoamine oxidase inhibitor ( MAOI ) ; least 14 day must elapse discontinuation MAOI initiation treatment bupropion ; current administration ( within past 30 day ) Wellbutrin , Wellbutrin SR , Wellbutrin XL .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 8, 2014</verification_date>
	<keyword>Tobacco</keyword>
	<keyword>Smoking</keyword>
	<keyword>Smoking Cessation</keyword>
	<keyword>Outcome</keyword>
	<keyword>Nicotine Dependence</keyword>
</DOC>